Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses

Rafael Holdings

29/10/2025 20:33

Overview

Rafael Holdings Q4 net loss widens to $12.1 mln due to acquisition-related expenses

Company's Q4 revenue was $350,000

Research and development expenses rose significantly due to Cyclo acquisition

Outlook

Rafael Holdings continues Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1

Result Drivers

ACQUISITION IMPACT - Consolidation of Cyclo Therapeutics' expenses contributed to increased R&D and administrative costs, widening net loss

FINANCIAL POSITION - $25 mln rights offering closed in June bolstered financial position for advancing Trappsol Cyclo program

R&D EXPENSES - R&D expenses rose to $7.5 mln in Q4 due to Cyclo acquisition and related activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$350,000
Q4 Net Income
-$12.05 mln
Q4 Operating Income
-$12.76 mln


Press Release: ID:nGNX6YltrT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)